Navigation Links
Express Scripts Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of WellPoint's NextRx Subsidiaries
Date:5/28/2009

Deal Passes Regulatory Hurdle

ST. LOUIS, May 28 /PRNewswire-FirstCall/ -- Today, Express Scripts, Inc. (Nasdaq: ESRX), announced that the waiting period required under the Hart-Scott-Rodino Act in connection with its premerger notification filing relating to its previously announced proposed acquisition of WellPoint, Inc.'s (NYSE: WLP) NextRx subsidiaries expired at 11:59 p.m. on May 27, 2009. This represents a significant step forward towards completion of the transaction. The transaction is expected to close in the second half of 2009 subject to satisfaction of the remaining closing conditions identified in the purchase agreement.

"With this step, we are much closer to utilizing our aligned business model, combined with the complementary expertise and capabilities of WellPoint to create significant growth opportunities for both companies," said George Paz, president, chief executive officer and chairman of Express Scripts.

About Express Scripts

Express Scripts is one of the largest full-service pharmacy benefit management companies in North America, providing healthcare management and administration services to HMOs, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans and government health programs. The Company assists plan sponsors in addressing access and affordability concerns resulting from rising drug costs while helping to improve health outcomes. The Company's integrated PBM services include network claims processing, home delivery services, patient care and direct specialty home delivery to patients, benefit design consultation, drug utilization review, formulary management, drug data analysis services, distribution of injectable drugs to patients' homes and physicians offices, bio-pharma services and other services.

Express Scripts is headquartered in St. Louis, Missouri. More information can be found at http://www.express-scripts.com, which includes expanded investor information and resources.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements, including, but not limited to, statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Factors that may impact these forward-looking statements can be found in the Management's Discussion and Analysis of Financial Condition and Results of Operations in our Form 10-Q on file with the SEC. A copy of this form can be found at the Investor Relations section of Express Scripts' web site at http://www.express-scripts.com.

We do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Express Scripts, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System
2. Clinic Service Announces Agreement to Provide Billing Service to MedExpress
3. Express Scripts to Present at Deutsche Bank Health Care Conference
4. AIDS Action Welcomes Presidents Budget Increases Yet Expresses Distress With Failure to End Federal Ban on Syringe Exchange Funding
5. Expression of infrared fluorescence engineered in mammals
6. War and Musculoskeletal Injury Prompt Artistic Expression
7. National Long Term Care Leaders Praise Overall Baucus Health Reform Effort, Express Specific Concerns Moving Forward
8. Express Scripts Reports First Quarter EPS of $0.86, up 23%
9. General Public and Physicians Express Similar Levels of Concern Regarding Potential Swine Flu Pandemic
10. Express Scripts Pharmacy Cost Trends Lowest in Over a Decade
11. ExpressMD(TM) Solutions Remote Patient Health Monitoring Device Receives 510(K) Market Clearance Approval From FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: